UNSPSC 51391713: Clorprenaline

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3W4327W76O. European Medicines Agency schedules Clorprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06766MIG. Clorprenaline generally arises in the molecular formula C11H16CLNO. The term CLORPRENALINE is an International Non-Proprietary Name or INN. CLORPRENALINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule clorprenaline under HS 29221980 and SITC 51461. As of Q4 2014, CLORPRENALINE remains the US FDA Preferred Term for this commodity. Clorprenaline bears US NLM identifiers UMLS ID C0055943 and NCI Concept Code C83633. SMILES: CC(C)NCC(C1=CC=CC=C1CL)O.

UNSPSC 51391713 Clorprenaline, a Commodity code, shows minimal recent activity aligned with its nominal scope. The two posted state and local opportunities under this code are unrelated to clorprenaline, a beta-2 agonist bronchodilator: one solicits naloxone and drug deactivation systems; the other is a request for information on direct-to-manufacturer prescription fulfillment programs. The mismatch between the code's pharmaceutical focus and the actual work being bought signals either miscoding in state procurement systems or tangential application of the code to broader pharmaceutical procurement categories that state and local buyers have not yet refined into purpose-specific codes.

Recent activity spans Florida and Texas, with Seminole County, Florida posting an IFB (solicitation number IFB60459723LAS, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, and the Texas Health and Human Services Commission posting an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs. Neither opportunity targets clorprenaline or respiratory therapeutics specifically. State and local procurement under this code warrants monitoring for coding correction or eventual refinement into subcategories, but current signals do not support near-term pursuit.